(Ebook PDF) Anti Aging Pharmacology 1st Edition by Vitaly Koltover ISBN 9780128236802 0128236809 full chapters

(Ebook PDF) Anti Aging Pharmacology 1st Edition by Vitaly Koltover-Ebook PDF Instant Download/Delivery:9780128236802, 0128236809

Instant download Full Chapter of Anti Aging Pharmacology 1st Edition after payment

Product details:

ISBN 10: 0128236809

ISBN 13: 9780128236802

Author: Vitaly Koltover

Anti-Aging Pharmacology provides an overview of current research aimed at the pharmacological modulation of aging, including a discussion of the growing number of novel drug classes with promising anti-aging potential. The aging process is the main risk factor for all chronic diseases affecting the elderly. With lifespans extending across the globe, these chronic diseases are placing a larger burden on individuals and health care systems. Therefore, slowing down the aging rate could be more effective in delaying aging-associated chronic disorders than combating them one by one, which is the conventional approach in a current disease-based pharmacological paradigm.

This book contains the work of the world’s leading researchers in the field, including sections on the conceptual and methodological background of anti-aging pharmacology, the basic classes of anti-aging drugs, phytochemicals, outcomes of anti-aging developments and future directions. This book will be of interest to a wide audience, ranging from pharmacologists, medicinal chemists and academic researchers in gerontology, biomedical sciences and those in medical practice.

Table of contents:

• Chapter 1. Geroscience—the concept
• 1. Introduction
• 2. Geroscience and anti-aging medicine
• 3. Anti-aging pharmacology: state of the art, unresolved issues, and perspectives
• 4. Human health span extension: the longevity dividend
• 5. Could aging be a treatable medical condition?
• 6. Concluding remarks
• Chapter 2. Basic pathways and targets for anti-aging intervention
• 1. Introduction
• 2. Molecular and cellular mechanisms of aging
• 3. Overview of RNA quality control in aging
• 4. Conclusions and future perspectives
• Chapter 3. Omics approaches in aging research
• 1. Introduction
• 2. Life expectancy clocks based on frailty indices
• 3. Epigenomics
• 4. Transcriptomics
• 5. Proteomics
• 6. Metabolomics
• 7. Ionomics
• 8. Cellular senescence
• 9. Gut microbiome
• 10. Conclusions and future perspectives
• Chapter 4. Metformin
• 1. Introduction
• 2. Metformin and health
• 3. Metformin and longevity
• 4. Cause for caution
• 5. Mechanisms of action
• 6. Conclusion
• Chapter 5. Rapamycin and rapalogs
• 1. Inhibition of mTOR signaling extends life span and promotes health span
• 2. The risks of rapamycin
• 3. Why does rapamycin have side effects?
• 4. A simple model: inhibition of mTORC1 is beneficial, inhibition of mTORC2 is detrimental
• 5. Specific targeting of mTORC1 signaling to promote healthy aging
• 6. Conclusion
• Chapter 6. Anti-aging effects of phenolic compounds
• 1. Introduction
• 2. Alzheimer’s disease
• 3. Other age-related diseases
• 4. Skin aging
• 5. Conclusions
• Chapter 7. Curcumin
• 1. Introduction
• 2. Phytochemicalsas anti-aging therapeutics: mechanistic considerations
• 3. Curcumin: from chemical structure to therapeutic efficacy
• 4. Curcumin in aging-associated pathology prevention
• 5. Conclusions
• Chapter 8. Pharmacology of NAD+boosters
• 1. Introduction
• 2. Overview of nicotinamide adenine dinucleotide biosynthesis pathways
• 3. Beneficial effects of nicotinamide adenine dinucleotide precursors in disease
• 4. Pharmacokinetics of nicotinamide adenine dinucleotideprecursors
• 5. Conclusions and future perspectives
• Chapter 9. Mitochondrial modulators
• 1. Introduction
• 2. Mitochondria and aging-related signaling pathways
• 3. Mitochondria, telomeres, and aging
• 4. Age-related changes in the mitochondrial genome
• 5. Age-related alteration of mitochondrial permeability
• 6. Mitochondrial dynamics in aging
• 7. Mitochondrial metabolism and caloric restriction
• 8. Mitochondrial metabolism and exercise
• 9. Mitochondria-modulating potential of prolongevity compounds
• 10. Conclusion
• Chapter 10. Nonsteroidal anti-inflammatory drugs
• 1. Introduction
• 2. Nonsteroidal anti-inflammatory drugs and diseases
• 3. Risks of long-term use of aspirin and other nonsteroidal anti-inflammatory drugs
• 4. Conclusions and future directions
• Chapter 11. Senolytics in diseases: killing to survive
• 1. Discovery of cellular senescence
• 2. Senescence in cancer
• 3. Senescence in cardiovascular disease
• 4. Senolytics in metabolic disease
• 5. Senolytics in liver disease
• 6. Senolytics in kidney disease
• 7. Senolytics in lung disease
• 8. Senolytics in neurodegenerative disease
• 9. Senolytics in bone disease
• 10. Senolytics in skin disease
• 11. Conclusion
• Chapter 12. Anti-aging skincare: the natural and organic way
• 1. Introduction
• 2. Current global trends
• 3. The effects of skin aging
• 4. Changes in connective tissues and skin surface pH in aging skin
• 5. Intrinsic and extrinsic aging factors
• 6. Natural and organic skincare
• 7. Natural anti-aging ingredients groups
• 8. Conclusion
• Chapter 13. Protein kinase modulation for anti-aging intervention
• 1. Introduction
• 2. Janus kinase/signal-transducing adapter model signaling pathway
• 3. P70 ribosomal protein S6 kinase
• 4. Hippo signaling pathway
• 5. Mitogen-activated protein kinase signaling pathway
• 6. Conclusions and future perspectives
• Chapter 14. The anti-aging mechanism of Berberine associated with metabolic control
• 1. Introduction
• 2. Mechanisms of berberine in targeting biological metabolic signaling
• 3. The clinical efficacy and side effects of berberine in age-related disease
• 4. Conclusions and future perspectives
• Chapter 15. Growth hormone
• 1. Introduction
• 2. Growth hormone
• 3. Impact of aging on the somatotropic axis
• 4. Physiological meaning of age-related changes in hormone levels
• 5. Effects of growth hormone (GH) administration in GH-deficient vs endocrinolgocially normal adults
• 6. Treatment with growth hormone may affect epigenetic age
• 7. Conclusions
• Chapter 16. Antioxidant pharmacology
• 1. Introduction
• 2. Free-radical hypothesis of aging: prelude
• 3. Free-radical malfunctions in oxidative metabolism
• 4. Free-radical redox-timer of aging in terms of system reliability theory
• 5. Antioxidant therapy: chemical background and experimental findings
• 6. Antioxidant therapy in light of system reliabi

People also search: 

anti-aging pharmacology
anti-aging primer
anticoagulants pharmacology pdf
a pharmacology primer
pharmacology an introduction 7th edition

Tags:

Anti Aging,Pharmacology,Vitaly Koltover